MedTrace Logo

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

NCT05043571 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-09-14

No results posted yet for this study

Summary

The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).

Conditions

  • Lymphoblastic Leukemia, Acute, Childhood
  • Lymphoblastic Leukemia
  • Lymphoblastic Leukemia, Acute Adult
  • Lymphoblastic Leukemia in Children
  • CAR
  • CAR T-Cell-Related Encephalopathy Syndrome
  • Refractory Leukemia

Interventions

BIOLOGICAL

CAR T-cell therapy

This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.

Sponsors & Collaborators

  • National University Hospital, Singapore

    lead OTHER

Principal Investigators

  • Allen Yeoh, M.D · National University Hospital, Singapore

  • Dario Campana, M.D, PhD · National University of Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-08
Primary Completion
2026-11-01
Completion
2026-11-01

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043571 on ClinicalTrials.gov